<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856644</url>
  </required_header>
  <id_info>
    <org_study_id>KSVGH-20561</org_study_id>
    <nct_id>NCT04856644</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB</brief_title>
  <acronym>ESCAPE-TB</acronym>
  <official_title>Evaluation of the Efficacy and Safety of a Short-course, Daily, 4-month Regimen Including Isoniazid, Pyrazinamide, Rifapentine and Moxifloxacin (2HZPM/2HPM) for the Treatment of Drug-susceptible Pulmonary Tuberculosis in Taiwan (ESCAPE-TB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of efficacious, safe, and shorter treatment regimens could significantly&#xD;
      improve TB management and treatment success rates. This prospective, 3-year, single arm study&#xD;
      is to evaluate the efficacy and safety of a short-course, 4-month regimen including&#xD;
      isoniazid(H), pyrazinamide(P), rifapentine (P), and moxifloxacin(M) (2HZPM/2HPM) for the&#xD;
      treatment of drug-susceptible, pulmonary tuberculosis, and compared with a historical control&#xD;
      group receiving the standard six-month regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shorter regimens have the potential to impact on TB control by reducing TB incidence and&#xD;
      mortality, and improve outcomes by increasing patient adherence to treatments and decreasing&#xD;
      duration to cure, in addition to reducing costs to the health system and the patient. The&#xD;
      purpose of this prospective, three year, single arm study is to evaluate whether a short&#xD;
      course, four-month regimen containing rifapentine and moxifloxacin (2HZPM/2HPM) are as&#xD;
      effective and/or as tolerable as the standard six-month regimen for the treatment of&#xD;
      drug-susceptible, pulmonary tuberculosis (TB). A historical group receiving the standard&#xD;
      six-month regimen is used as control. The pharmacokinetic and pharmacodynamic profile of&#xD;
      rifapentine in Asian patients. Analysis of of histocompatibility leucocyte antigen (HLA)&#xD;
      associations with adverse events and changes in biomarkers will be done.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The intervention group: all patients recruited into the study will receive the 4-month regimen The comparator group: historical control in those who received the standard 6-month regimen</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Masking will not be done</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Efficacy</measure>
    <time_frame>12 months after study treatment assignment</time_frame>
    <description>TB disease-free survival at 12 months after study treatment assignment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>0-4 months</time_frame>
    <description>The proportion of participants with grade 3 or higher adverse events during study drug treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early sterilizing activity</measure>
    <time_frame>8 weeks</time_frame>
    <description>The proportion of patients with a negative sputum culture at the end of intensive phase therapy at 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum culture conversion</measure>
    <time_frame>4, 8, 12, 17 weeks, 6 months, 12 months</time_frame>
    <description>Time to stable sputum culture conversion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speed of decline of sputum viable bacilli</measure>
    <time_frame>2-8 weeks</time_frame>
    <description>Speed of decline of sputum viable bacilli by automated mycobacteria growth indicator tube (MGIT) days to detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB disease-free survival at 12 months sensitivity analysis (unfavorable outcome)</measure>
    <time_frame>12 months</time_frame>
    <description>TB disease-free survival at 12 months after study treatment assignment assuming all losses to follow-up and non-TB deaths have an unfavorable outcome (Sensitivity analyses assuming all losses to follow-up and non-TB deaths have an unfavorable outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB disease-free survival at 12 months sensitivity analysis (favorable outcome)</measure>
    <time_frame>12 months</time_frame>
    <description>TB disease-free survival at 12 months after study treatment assignment assuming all losses to follow-up and non-TB deaths have an favorable outcome (Sensitivity analyses assuming all losses to follow-up and non-TB deaths have an favorable outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment discontinuation</measure>
    <time_frame>0-4 months</time_frame>
    <description>Rates of treatment discontinuation for reasons other than ineligibility (late exclusions due to drug resistance or HIV status)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>4, 12 months</time_frame>
    <description>All-cause mortality at 4 months and 12 months post-treatment assignment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attributable mortality</measure>
    <time_frame>4, 12 months</time_frame>
    <description>Attributable mortality at 4 months and 12 months post-treatment assignment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in interferon-gamma levels</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Changes in interferon-gamma levels during treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in tumor necrosis factor-alpha levels</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Changes in tumor necrosis factor-alpha levels during treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in interleukin-12 and interleukin-6 levels</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Changes in interleukin-12 and interleukin-6 levels during treatment compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triggering receptor expressed on myeloid cells-1 (TREM-1) levels</measure>
    <time_frame>2, 4, 8, 12 weeks</time_frame>
    <description>Changes in triggering receptor expressed on myeloid cells-1 (TREM-1) levels during treatment compared to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HLA associations with severe drug adverse events</measure>
    <time_frame>0-4 months</time_frame>
    <description>HLA Genotyping to detect predictors for occurrence of severe drug adverse events including skin rash and hepatitis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum plasma concentration (Cmax) of rifapentine</measure>
    <time_frame>0, 2, 4, 8, 12 weeks</time_frame>
    <description>Serum concentration of rifapentine by determining area under the curve</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>4-month regimen (2HZPM/2HPM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight weeks of daily treatment with isoniazid (H), pyrazinamide (Z), rifapentine (P), and moxifloxacin (M), followed by&#xD;
Nine weeks of daily treatment with isoniazid, rifapentine and moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard 6-month regimen (2HERZ/4HR) historical control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>a standard, six-month regimen, with&#xD;
Eight weeks of daily treatment with isoniazid (H), rifampin (R), pyrazinamide (Z) and ethambutol (E) followed by&#xD;
Eighteen weeks of daily treatment with isoniazid and rifampin, with or without ethambutol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4-month rifapentine-based regimen</intervention_name>
    <description>8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin</description>
    <arm_group_label>4-month regimen (2HZPM/2HPM)</arm_group_label>
    <other_name>rifapentine</other_name>
    <other_name>moxifloxacin</other_name>
    <other_name>priftin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Suspected newly diagnosed pulmonary TB plus one of the following: a) at least one&#xD;
             sputum specimen positive for acid-fast bacilli on smear microscopy OR b) at least one&#xD;
             sputum specimen positive for Mycobacterium tuberculosis by culture or &quot;Gene Xpert&#xD;
             MTB/RIF&quot; testing, with rifamycin resistance not detected, OR c) histopathologic&#xD;
             findings compatible with mycobacterial infection including a positive acid-fast stain&#xD;
&#xD;
          2. Patient with a history of being untreated for 3 years after cure from a previous&#xD;
             episode of TB can be included.&#xD;
&#xD;
          3. Age 20 years or older&#xD;
&#xD;
          4. For women of childbearing potential, a negative pregnancy test at or within seven (7)&#xD;
             days prior to screening is required, and must agree to practice a barrier method of&#xD;
             contraception during study drug treatment, or be surgically sterilized or have an&#xD;
             intrauterine contraceptive device in place.&#xD;
&#xD;
          5. Laboratory parameters performed at or within 14 days prior to enrollment:&#xD;
&#xD;
               -  Serum or plasma alanine aminotransferase (ALT) less than or equal to 3 times the&#xD;
                  upper limit of normal&#xD;
&#xD;
               -  Serum or plasma total bilirubin less than or equal to 2.5 times the upper limit&#xD;
                  of normal&#xD;
&#xD;
               -  Serum or plasma creatinine level less than or equal to 2 times the upper limit of&#xD;
                  normal or Creatinine clearance (CrCl) level greater than 30 mL/min.&#xD;
&#xD;
               -  Serum or plasma potassium level greater than or equal to 3.5 milliequivalent/L&#xD;
&#xD;
               -  Hemoglobin level of 7.0 g/dL or greater&#xD;
&#xD;
               -  Platelet count of 100,000/mm3 or greater&#xD;
&#xD;
          6. Patient signed a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast-feeding.&#xD;
&#xD;
          2. Unable to take oral medications.&#xD;
&#xD;
          3. Previously enrolled in this study.&#xD;
&#xD;
          4. Received any investigational drug in the past 3 months.&#xD;
&#xD;
          5. More than 14 days of systemic treatment with any antituberculous drugs preceding&#xD;
             initiation of study drugs.&#xD;
&#xD;
          6. Known history of prolonged QT syndrome.&#xD;
&#xD;
          7. Suspected or documented TB involving the central nervous system and/or bones and/or&#xD;
             joints, and/or miliary tuberculosis and/or pericardial tuberculosis.&#xD;
&#xD;
          8. Weight less than 40.0 kg.&#xD;
&#xD;
          9. Known allergy or intolerance to any of the study medications.&#xD;
&#xD;
         10. Individuals will be excluded from enrollment if, at the time of enrollment, their M.&#xD;
             tuberculosis isolate is already known to be resistant to any one or more of the&#xD;
             following: rifampin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones.&#xD;
&#xD;
         11. Medical conditions, including HIV infection and others conditions that, in the&#xD;
             investigator's judgment, make study participation not in the individual's best&#xD;
             interest.&#xD;
&#xD;
         12. Late exclusions: Drug-resistant TB by either rapid sputum based test (Gene Expert) or&#xD;
             resistance testing using an indirect susceptibility test in liquid culture to&#xD;
             isoniazid, rifampin, ethambutol, pyrazinamide or resistance to moxifloxacin or&#xD;
             rifapentine by microdilution agar proportion test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Shin-Jung Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Shin-Jung Lee, M.D., Ph.D.</last_name>
    <phone>+886-7342-2121</phone>
    <phone_ext>2029</phone_ext>
    <email>ssjlee28@yahoo.com.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hsin-Wei Tung, R.N.</last_name>
    <phone>+886-7342-2121</phone>
    <phone_ext>2062</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan Shin-Jung Lee, M.D., Ph.D.</last_name>
      <phone>+886-7342-2121</phone>
      <phone_ext>2029</phone_ext>
      <email>ssjlee28@yahoo.com.tw</email>
    </contact>
    <contact_backup>
      <last_name>Hsin-Wei Tung, R.N.</last_name>
      <phone>+886-73422121</phone>
      <phone_ext>2062</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Susan Shin-Jung Lee, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao-Shen Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Chin Tsai, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jui-Kuang Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Len Sy, M.D., BSMT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kuan-Sheng Wu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Ting Tseng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ya-Wei Weng, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Chen Chou, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huan-Yi Wu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Jia-Yih Feng, M.D.</last_name>
      <phone>+886-2871-2121</phone>
      <phone_ext>7564</phone_ext>
    </contact>
    <investigator>
      <last_name>Jia-Yih Feng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheng-Wei Pan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Chin-Chung Shu, M.D.</last_name>
      <phone>+886-2312-3456</phone>
      <phone_ext>65132</phone_ext>
    </contact>
    <investigator>
      <last_name>Chin-Chung Shu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan City</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>Tsai-Yu Wang, M.D.</last_name>
      <phone>+886-3-3281200</phone>
      <phone_ext>8470</phone_ext>
    </contact>
    <investigator>
      <last_name>Tsai-Yu Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chung-Shu Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Po-Jui Chang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meng-Heng Hsieh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Susan Shin-Jung Lee</investigator_full_name>
    <investigator_title>Attending physiciian, Division of Infectious Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

